🔗 Share this article

Given that America continues making unprecedented changes to its immunization guidelines, a particular individual has emerged somewhat surprisingly: Tracy Beth Høeg, a Danish American sports physician and public health researcher who initially gained attention by casting doubt on COVID-19 vaccinations in the pandemic and has concentrated on alleged deaths following COVID-19 vaccination in her short time at the US Food and Drug Administration (FDA).

Planned Shifts to Childhood Vaccine Program

Public health authorities had intended to unveil sweeping changes to the pediatric immunization program in December, aligning the US with Denmark’s vaccine program, sources say – a significant shift that would put the US at odds with much of the international standard with little proof for benefit. The announcement has been pushed back until the coming year.

Instead of the director of the vaccine center, Tracy Beth Høeg is listed to present at the meeting. She was recently named acting director of the FDA’s CDER, the fifth appointee to head the division this calendar year.

A New Direction at the Regulatory Body

This interim role might represent a closer partnership between the drug and biologics branches as Dr. Høeg and Dr. Prasad solidify control at the regulatory agency – and it points to a renewed priority upon reevaluating already-approved vaccines at the FDA.

Dr. Høeg has repeatedly called for halting certain pediatric vaccine recommendations in the US to become more like Denmark, a country with comprehensive healthcare and a population about the size of the state of Wisconsin.

To date comments, she has continued to focus on vaccination policy – traditionally the responsibility of Dr. Prasad, chief of the FDA’s vaccine center – instead of medication approval.

Doubts Over Background

Høeg has no apparent experience in pharmaceutical research, regulation or leadership, which has been standard for former leaders of the CBER. She has been employed at the FDA as a top consultant to the FDA chief and CBER since spring.

“It seems she lacks to have the necessary background” for running the drug-regulation department, stated Dr. Jonathan Howard. “She lacks experience running a clinical trial. She lacks experience in leading a major agency. She lacks background in industry regulation.”

Past directors of the center would “grasp laws and regulations and the science of medication creation”, commented Dr. Janet Woodcock. “Clearly, she doesn’t have the kind of background that prior appointees who led CBER have had.”

This division has an enormous workload at the agency, Woodcock stated.

“Everybody just focuses on the innovative therapies, but the generic drug division clears a multitude of generic medications. There’s a biologic copycat branch, OTC medication office and so forth, and each of these have to be managed,” Woodcock explained. “The thing you neglect, that is the part that I always told people is going to cause problems.”

There is also, a significant leadership element to the position, which manages in excess of 5,000 employees. “It’s a huge leadership role, if you execute it properly,” the former official concluded.

Agency Reaction and Disputed Policies

Regarding inquiries about Høeg’s fitness for the role and whether this assignment indicates more teamwork among FDA leaders on immunizations, a press secretary responded that the “concerns are based on inaccurate presumptions”.

“Her resume matches the responsibilities of her role,” the representative stated, pointing to the months Høeg spent counseling the agency head on “drug safety and approval science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's new expedited review system, a contentious rapid therapy clearance system that apparently troubled her preceding directors. “By what process are these therapies being selected for this fast-track system? Who is making the calls?” Howard asked. “There’s a lot of confidentiality happening at the regulatory body right now.”

In general, he stated, “the Food and Drug Administration appears to be shifting towards less stringent rules of pharmaceuticals, with the exception of immunizations.”

Established History on Immunizations

Regarding immunizations, Høeg has a more documented, if troubling, past, critics observe. She released a study using unconfirmed public submissions to determine the frequency of myocarditis after COVID-19 vaccination. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who reportedly have changed statistics to indicate Covid vaccines are riskier than they are.

Part of her “desired changes” for the incoming government featured altering regulations for recently developed shots and discontinuing “optional” immunizations, she remarked following the vote on a podcast. At the agency, Høeg has allegedly floated the idea of preventing adolescent males from getting COVID-19 vaccines.

“She’s an thorough true believer who starts off with her preconceived notions and works backwards to fit the data in a highly disingenuous, fraudulent fashion,” Howard argued.

Taking Control and a “Campaign of Retribution”

Dr. Høeg joined fellow dissenters, {like|